Factor IX Concept

subject area of

• A DNA marker closely linked to the factor IX (haemophilia B) gene  Journal Articles
• A case of non‐resolving hemophilia B Leyden in a 42‐year‐old male (F9 promoter + 13 A>G)  Journal Articles
• A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred  Journal Articles
• A therapeutic alternative for haemophiliacs with inhibitors  Journal Articles
• Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV  Journal Articles
• Age‐related changes in factor VII proteolysis in vivo  Journal Articles
• An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice  Conferences
• Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)  Journal Articles
• Assessments of outcome in haemophilia – a patient perspective  Journal Articles
• Cardiac surgery in patients with haemophilia B: a case report and review of the literature  Journal Articles
• Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules  Journal Articles
• Comparing bleed frequency and factor concentrate use between haemophilia A and B patients  Journal Articles
• Comparing hand‐held computers and paper diaries for haemophilia home therapy: a randomized trial  Journal Articles
• Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy  Journal Articles
• Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers  Journal Articles
• Continuous antigenic stimulation system (CASS) as a new immunization strategy  Journal Articles
• Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine^®) in haemophilia B  Journal Articles
• Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption  Journal Articles
• Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B  Journal Articles
• Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project  Journal Articles
• Diagnosis and treatment of intracranial hemorrhage in children with hemophilia  Journal Articles
• Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment  Journal Articles
• Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.  Journal Articles
• Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits  Conferences
• Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery  Journal Articles
• Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice  Journal Articles
• Encapsulation of Recombinant Cells with a Novel Magnetized Alginate for Magnetic Resonance Imaging  Journal Articles
• Enhancement of myoblast microencapsulation for gene therapy  Journal Articles
• Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH  Journal Articles
• Expression of Human Factor IX by Microencapsulated Recombinant Fibroblasts  Journal Articles
• Factor IX pharmacokinetics: differences between plasma‐derived and recombinant products and the clinical and economic implications: a meeting report  Conferences
• Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells  Journal Articles
• Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding  Journal Articles
• Gene Therapy for Hemophilia  Journal Articles
• Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.  Journal Articles
• Haemophilia in a real‐world setting: the value of clinical experience in data collection  Journal Articles
• Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.  Journal Articles
• Hemophilia in the 1990s: Principles of Management and Improved Access to Care  Journal Articles
• High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice  Journal Articles
• Immune tolerance induction for a patient with factor IX inhibitors - a case report  Journal Articles
• Joint WFH‐ISTH session: issues in clinical trial design  Journal Articles
• Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children  Journal Articles
• Low Dose Prophylaxis vis-a-vis on-Demand Treatment Strategies for Hemophilia: A Cost Effective and Disability Attenuating Approach.  Journal Articles
• Low prevalence of inhibitor antibodies in the Canadian haemophilia population  Journal Articles
• Modulation of intrinsic prothrombin activation by fibrinogen and fibrin I.  Journal Articles
• Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran  Conferences
• New anticoagulants  Conferences
• Nonautologous gene therapy with implantable devices  Journal Articles
• Nonviral Gene Therapy Approaches to Hemophilia  Journal Articles
• On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome  Journal Articles
• Orthotopic liver transplantation in a patient with combined hemophilia A and B  Journal Articles
• Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B  Journal Articles
• Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable Microcapsules  Journal Articles
• Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B  Journal Articles
• Propagating factor IX-producing hepatocytes for haemophilia B therapy  Journal Articles
• Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH  Journal Articles
• Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.  Journal Articles
• Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose  Journal Articles
• Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis  Journal Articles
• Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells  Journal Articles
• Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells  Journal Articles
• Switching patients in the age of long-acting recombinant products?  Journal Articles
• Switching to extended half‐life products in Canada – preliminary data  Journal Articles
• Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates  Journal Articles
• Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement  Journal Articles
• Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database  Journal Articles
• The Genetic Distance between the Coagulation Factor IX Gene and the Locus for the Fragile X Syndrome: Clinical Implications  Journal Articles
• The current state of adverse event reporting in hemophilia  Journal Articles
• The factor VIII-independent activation of factor X by factors IXa and VII in plasma  Journal Articles
• The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III  Journal Articles
• The isolation of prothrombin, factor IX and factor X from human factor IX concentrates  Journal Articles
• The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey  Journal Articles
• Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics  Journal Articles
• Urokinase Therapy: Dosage Schedules and Coagulant Side Effects  Journal Articles